A phase 3, randomized, double-blind study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous, non-small cell lung cancer (NSCLC) (#590)
Laufzeit: 01.01.2015 - 31.12.2018
imported
Kurzfassung
A phase 3, randomized, double-blind study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous, non-small cell lung cancer (NSCLC)
